DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-043/S-005

Bayer HealthCare LLC, Consumer Care Division
Attn: Jennifer T. Mahilo
Senior Regulatory Specialist, Regulatory Affairs
36 Columbia Rd
Morristown, NJ 07962-1910

Dear Ms. Mahilo:

Please refer to your supplemental new drug application dated June 28, 2004, received June 29, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for RID Mousse (0.33% pyrethrins and 4.0% piperonyl butoxide) Topical Aerosolized Foam.

We acknowledge receipt of your submissions dated July 16, and December 14, 2004.

This supplemental new drug application proposes labeling changes for the RID Mousse carton, can, and consumer information insert to comply with the Federal Register publication entitled "Pediculicide Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph" [68FR75414].

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (consumer information insert submitted on June 28, 2004, and immediate container and carton labels submitted on December 14, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-043/S-005." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call LCDR Keith Olin, Regulatory Project Manager, at (301) 827-2293.

Sincerely,

{See appended electronic signature page}

Curtis Rosebraugh, M.D., M.P.H.
Deputy Director
Division of Over-the-Counter Drug Products
Office of Drug Evaluation V

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Curtis Rosebraugh

12/20/04 03:40:08 PM